Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Nurix Therapeutics, Inc.NRIX · Entity 1156 | Director | May 15, 2026 | May 15, 2026 |
| Rapport Therapeutics, Inc.RAPP · Entity 4394 | Director | June 10, 2026 | June 10, 2026 |
| VERTEX PHARMACEUTICALS INC / MAVRTX · Entity 2875 | SVP & Chief Accounting Officer | February 26, 2021 | March 02, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Nurix Therapeutics, Inc.
Report date May 15, 2026 · Filed May 15, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.86 · Expires 2036-05-14 | Direct | 31,250 |
Reported balance
After 2026-05-15 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-15 · Grant · Acquired 31,250 · Balance 31,250 F1: The stock option vests as to 100% of the award on the earlier of (a) the date of the next annual meeting of the Issuer's stockholders and (b) May 15, 2027, in each case, subject to the Reporting Person's provision of service to the Issuer on such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock option vests as to 100% of the award on the earlier of (a) the date of the next annual meeting of the Issuer's stockholders and (b) May 15, 2027, in each case, subject to the Reporting Person's provision of service to the Issuer on such vesting date.
Rapport Therapeutics, Inc.
Report date June 10, 2026 · Filed June 10, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $35.21 · Expires 2036-06-10 | Direct | 15,200 |
Reported balance
After 2026-06-10 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-10 · Grant · Acquired 15,200 · Balance 15,200 F1: The shares underlying this option shall vest upon the earlier of (i) June 10, 2027 and (ii) the date of the next Annual Meeting of Stockholders of the Issuer, subject to the Reporting Person's continued service on such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares underlying this option shall vest upon the earlier of (i) June 10, 2027 and (ii) the date of the next Annual Meeting of Stockholders of the Issuer, subject to the Reporting Person's continued service on such vesting date.
VERTEX PHARMACEUTICALS INC / MA
Report date February 26, 2021 · Filed March 02, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 9,884 |
Ending reported balance
After 2021-03-01 transaction · row 5
5 source rows · reconciled sequenceRow 1 · 2021-02-26 · Tax withholding · Disposed 2,218 · Balance 12,666 Row 2 · 2021-03-01 · Sale · Disposed 1,026 · Balance 11,640 F1: Transaction made pursuant to Mr. Silva's company approved trading plan under Rule 10b5-1. F2: Open market sales reported on this line occurred at a weighted average price of $210.13 (range $209.93 to $210.77). F3: Mr. Silva undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Row 3 · 2021-03-01 · Sale · Disposed 610 · Balance 11,030 F1: Transaction made pursuant to Mr. Silva's company approved trading plan under Rule 10b5-1. F3: Mr. Silva undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4: Open market sales reported on this line occurred at a weighted average price of $211.45 (range $210.96 to $211.95). Row 4 · 2021-03-01 · Sale · Disposed 915 · Balance 10,115 F1: Transaction made pursuant to Mr. Silva's company approved trading plan under Rule 10b5-1. F3: Mr. Silva undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5: Open market sales reported on this line occurred at a weighted average price of $212.51 (range $211.96 to $212.85). Row 5 · 2021-03-01 · Sale · Disposed 231 · Balance 9,884 F1: Transaction made pursuant to Mr. Silva's company approved trading plan under Rule 10b5-1. F3: Mr. Silva undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F6: Open market sales reported on this line occurred at a weighted average price of $213.12 (range $212.96 to $213.27). |
| Common StockSEC Table I · non-derivative | Indirect401(k) | 169 |
Reported balance
Holding disclosure · report date 2021-02-26 · row 6
Holding and transaction disclosures are not merged.
1 source rowRow 6 · Balance 169 |
Filing footnotes · ownership attribution and instrument terms
F1: Transaction made pursuant to Mr. Silva's company approved trading plan under Rule 10b5-1.
F2: Open market sales reported on this line occurred at a weighted average price of $210.13 (range $209.93 to $210.77).
F3: Mr. Silva undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
F4: Open market sales reported on this line occurred at a weighted average price of $211.45 (range $210.96 to $211.95).
F5: Open market sales reported on this line occurred at a weighted average price of $212.51 (range $211.96 to $212.85).
F6: Open market sales reported on this line occurred at a weighted average price of $213.12 (range $212.96 to $213.27).
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 17, 2011 Filed May 18, 2011 17:47 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 467 | $56.63 | $26,446.21 |
DisclosureSEC source: 0001209191-11-029276 · doc4.xml · nonDerivative · entry 1 Silva Paul M · CIK 0001446372 · VP & Corp Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,734 F1 · kind: Transaction made pursuant to Mr. Silva's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $56.63 (range $56.34 to $56.99). F3 · price: Mr. Silva undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| March 10, 2011 Filed Mar 11, 2011 16:07 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 600 | $46.24 | $27,744.00 |
DisclosureSEC source: 0001209191-11-017266 · doc4.xml · nonDerivative · entry 2 Silva Paul M · CIK 0001446372 · VP & Corp Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,500 F1 · kind: Transaction made pursuant to Mr. Silva's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Silva undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $46.24 (range $46.03 to $46.70). Read SEC document |
| March 10, 2011 Filed Mar 11, 2011 16:07 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 1,525 | $45.73 | $69,738.25 |
DisclosureSEC source: 0001209191-11-017266 · doc4.xml · nonDerivative · entry 1 Silva Paul M · CIK 0001446372 · VP & Corp Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,100 F1 · kind: Transaction made pursuant to Mr. Silva's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $45.73 (range $45.22 to $45.99). F3 · price: Mr. Silva undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| February 03, 2011 Filed Feb 7, 2011 19:58 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantStock Option · Derivative | 15,000 | $0.00 Strike: $38.80 | $0.00 |
DisclosureSEC source: 0000875320-11-000014 · edgar.xml · derivative · entry 3 Silva Paul M · CIK 0001446372 · V.P. and Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2021-02-02 F2 · derivative.exercise_date: Right to buy under 2006 Stock and Option Plan, vesting in 16 quarterly installments from 02/03/2011. Read SEC document |
| February 03, 2011 Filed Feb 7, 2011 19:58 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 3,000 | $0.01 | $30.00 |
DisclosureSEC source: 0000875320-11-000014 · edgar.xml · nonDerivative · entry 1 Silva Paul M · CIK 0001446372 · V.P. and Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,625 F1 · shares: Stock grant under 2006 Stock and Option Plan, vesting on 2/3/2015, subject to (i) earlier acceleration of 50% of shares upon (A) receiving U.S. and E.U. marketing approval for VX-770 or (B) reaching specified telaprevir sales levels during 18 months following its U.S. launch; and (ii) earlier acceleration of 50% of shares upon (1) acceptance by the FDA of an NDA for a treatment regimen that includes telaprevir and VX-222; (2) initiation of a pivotal trial for a drug candidate for which the Company has U.S. commercialization rights in an indication that is not HCV infection or CF; or (3) reaching specified telaprevir sales levels during 18 months following its U.S. launch. Read SEC document |
| November 15, 2010 Filed Nov 16, 2010 21:21 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 570 | $34.46 | $19,642.20 |
DisclosureSEC source: 0000875320-10-000059 · edgar.xml · nonDerivative · entry 1 Silva Paul M · CIK 0001446372 · V.P. and Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,625 F1 · kind: Transaction made pursuant to Mr. Silva's company approved trading plan established under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a wieghted average price of $34.46 (range $34.30 to $34.61). F3 · price: Mr. Silva undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| July 14, 2010 Filed Jul 16, 2010 19:57 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantStock Options · Derivative | 7,500 | $0.00 Strike: $33.82 | $0.00 |
DisclosureSEC source: 0000875320-10-000046 · edgar.xml · derivative · entry 1 Silva Paul M · CIK 0001446372 · V.P. and Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Underlying: Common Stock · 7,500 shares Expires 2020-07-13 F1 · derivative.exercise_date: Right to buy under 2006 Stock and Option Plan, vesting in 16 quarterly installments from 07/14/2010. Read SEC document |
| May 18, 2010 Filed May 19, 2010 19:35 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 526 | $37.61 | $19,782.86 |
DisclosureSEC source: 0000875320-10-000024 · edgar.xml · nonDerivative · entry 1 Silva Paul M · CIK 0001446372 · V.P. and Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,625 F1 · kind: Transaction made pursuant to Mr. Silva's company approved trading plan established under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a wieghted average price of $37.61 (range $37.27 to $38.00). F3 · price: Mr. Silva undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| February 04, 2010 Filed Feb 8, 2010 18:48 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantStock Option · Derivative | 22,500 | $0.00 Strike: $39.05 | $0.00 |
DisclosureSEC source: 0000875320-10-000010 · edgar.xml · derivative · entry 3 Silva Paul M · CIK 0001446372 · V.P. and Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,500 Underlying: Common Stock · 22,500 shares Expires 2020-02-03 F2 · shares: Stock option under 2006 Stock and Option Plan, vesting in 16 equal quarterly installments over four years. Read SEC document |
| February 04, 2010 Filed Feb 8, 2010 18:48 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 3,000 | $0.01 | $30.00 |
DisclosureSEC source: 0000875320-10-000010 · edgar.xml · nonDerivative · entry 1 Silva Paul M · CIK 0001446372 · V.P. and Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,625 F1 · shares: Stock grant under 2006 Stock and Option Plan, vesting on 2/4/2014, subject to 50% acceleration upon receiving U.S. marketing approval for telaprevir; and to 50% acceleration upon either (a) reaching specified telaprevir sales levels during 18 months following its U.S. launch or (b) launch of any additional drug beyond telaprevir prior to December 31, 2012. Read SEC document |
| November 18, 2009 Filed Nov 20, 2009 21:37 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 719 | $39.70 | $28,544.30 |
DisclosureSEC source: 0000875320-09-000099 · edgar.xml · nonDerivative · entry 1 Silva Paul M · CIK 0001446372 · V.P. and Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,625 Read SEC document |
| August 14, 2009 Filed Aug 17, 2009 17:29 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 750 | $33.99 | $25,492.50 |
DisclosureSEC source: 0000875320-09-000077 · edgar.xml · nonDerivative · entry 1 Silva Paul M · CIK 0001446372 · V.P. and Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,625 F1 · kind: Transaction made pursuant to Mr. Silva's company approved trading plan established under Rule 10b5-1. Read SEC document |
| July 27, 2009 Filed Jul 28, 2009 17:04 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 125 | $35.68 | $4,460.00 |
DisclosureSEC source: 0000875320-09-000070 · edgar.xml · nonDerivative · entry 1 Silva Paul M · CIK 0001446372 · V.P. and Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,375 F1 · kind: Transaction made pursuant to Mr. Silva's company approved trading plan established under Rule 10b5-1. Read SEC document |
| July 16, 2009 Filed Jul 20, 2009 19:35 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantStock Option · Derivative | 7,500 | $0.00 Strike: $33.28 | $0.00 |
DisclosureSEC source: 0000875320-09-000067 · edgar.xml · derivative · entry 1 Silva Paul M · CIK 0001446372 · V.P. and Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Underlying: Common Stock · 7,500 shares Expires 2019-07-15 F1 · derivative.exercise_date: Right to buy under 2006 Stock and Option Plan, vesting in 16 quarterly installments from 07/16/09. Read SEC document |
| May 18, 2009 Filed May 19, 2009 18:31 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 468 | $28.44 | $13,309.92 |
DisclosureSEC source: 0000875320-09-000035 · edgar.xml · nonDerivative · entry 1 Silva Paul M · CIK 0001446372 · V.P. and Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,500 F1 · kind: Transaction made pursuant to Mr. Silva's company approved trading plan established under Rule 10b5-1. Read SEC document |
| February 09, 2009 Filed Feb 10, 2009 21:12 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 250 | $33.69 | $8,422.50 |
DisclosureSEC source: 0000875320-09-000015 · edgar.xml · nonDerivative · entry 1 Silva Paul M · CIK 0001446372 · V.P. and Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,500 F1 · shares: Transaction made pursuant to Mr. Silva's company approved trading plan established under Rule 10b5-1. Read SEC document |
| February 05, 2009 Filed Feb 6, 2009 21:32 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantStock Option · Derivative | 15,000 | $0.00 Strike: $33.55 | $0.00 |
DisclosureSEC source: 0000875320-09-000013 · edgar.xml · derivative · entry 3 Silva Paul M · CIK 0001446372 · V.P. and Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2019-02-04 F2 · derivative.exercise_date: Right to buy under 2006 Stock and Option Plan, vesting in 16 quarterly installments from 02/05/09. Read SEC document |
| February 05, 2009 Filed Feb 6, 2009 21:32 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 2,000 | $0.01 | $20.00 |
DisclosureSEC source: 0000875320-09-000013 · edgar.xml · nonDerivative · entry 1 Silva Paul M · CIK 0001446372 · V.P. and Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,750 F1 · shares: Stock grant made under 2006 Stock and Option Plan, vesting on 2/5/2013, subject to 50% acceleration upon filing a new drug application with the FDA for telaprevir and 50% acceleration upon the approval of a new drug application for telaprevir. Read SEC document |
| November 18, 2008 Filed Nov 19, 2008 21:29 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 218 | $26.13 | $5,696.34 |
DisclosureSEC source: 0000875320-08-000090 · edgar.xml · nonDerivative · entry 1 Silva Paul M · CIK 0001446372 · V.P. and Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,750 F1 · kind: Transaction made pursuant to Mr. Silva's company approved trading plan established under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a wieghted average price of $26.13 (range $25.75 to $26.53). F3 · price: Mr. Silva undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.